KPRX
What one share of Kiora Pharmaceuticals holds
Pharmaceutical Preparations
We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP.
Kiora Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.32 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.82 |
| Cash and investments | $1.60 |
| Book value | $3.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$906.29 | $0.00 | −$571.42 | — | −$19.51 |
| 2017 | — | −$556.15 | $1.56 | −$273.72 | — | −$67.00 |
| 2018 | — | −$182.81 | $0.34 | −$183.71 | — | $117.64 |
| 2019 | — | −$89.24 | $0.00 | −$102.53 | — | $64.96 |
| 2020 | $0.11 | −$59.78 | $0.17 | −$63.92 | — | $70.04 |
| 2021 | $0.00 | −$57.12 | $0.26 | −$44.54 | — | $46.05 |
| 2022 | — | −$18.55 | $0.00 | −$14.24 | — | — |
| 2023 | $0.00 | −$24.25 | $0.00 | −$17.76 | — | $7.14 |
| 2024 | $3.88 | $0.87 | $0.00 | $2.07 | — | $8.58 |
| 2025 | $0.00 | −$2.64 | $0.03 | −$2.45 | — | $4.29 |